Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. David SoergelExec. VP & Chief Medical Officer | -1,04k | 516,56k | Automatic Disposition | 495,74 | 10,03k | -9,41% |
| 2026-05-22 | Dr. Richard S. LevyIndependent Director | -5,68k | 2,93M | Automatic Disposition | 506,68 - 519,98 | 21,30k | -21,06% |
| 2026-05-18 | Dr. David SoergelExec. VP & Chief Medical Officer | -844,00 | 435,42k | Verkauf | 515,90 | 11,08k | -7,08% |
| 2026-03-06 | Ms. Mardi C. DierExec. VP & CFO | -646,00 | 279,03k | Verkauf | 431,94 | 0,00 | -100,00% |
| 2026-03-06 | Ms. Mardi C. DierExec. VP & CFO | -1,34k | 574,96k | Automatic Disposition | 425,08 - 437,65 | 0,00 | -100,00% |
| 2026-03-06 | Mr. William J. SiboldCEO, President & Director | -1,66k | 718,32k | Verkauf | 431,94 | 105,91k | -1,55% |
| 2026-03-06 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -360,00 | 155,50k | Verkauf | 431,94 | 1,82k | -16,51% |
| 2026-03-06 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -419,00 | 180,98k | Verkauf | 431,94 | 427,00 | -49,53% |
| 2026-03-06 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -491,00 | 212,08k | Verkauf | 431,94 | 441,03k | -0,11% |
| 2026-03-02 | Ms. Mardi C. DierExec. VP & CFO | -1,18k | 505,39k | Verkauf | 427,21 | 1,04k | -53,31% |
| 2026-02-23 | Dr. Richard S. LevyIndependent Director | 2,50k | 18,40k | Derivative Exercise and Retained Stock | 7,36 | 26,98k | 10,21% |
| 2026-01-26 | Dr. Richard S. LevyIndependent Director | 4,00k | 65,84k | Derivative Exercise and Retained Stock | 16,46 | 24,48k | 19,53% |
| 2026-01-26 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -340,00 | 167,42k | Verkauf | 492,42 | 9,12k | -3,59% |
| 2026-01-26 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -570,00 | 281,92k | Automatic Disposition | 494,59 | 9,12k | -5,88% |
| 2026-01-26 | Mr. William J. SiboldCEO, President & Director | -1,58k | 776,55k | Verkauf | 492,42 | 104,31k | -1,49% |
| 2026-01-26 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -647,00 | 318,60k | Verkauf | 492,42 | 440,43k | -0,15% |
| 2026-01-20 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -263,00 | 129,07k | Verkauf | 490,77 | 1,38k | -15,98% |
| 2026-01-20 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -429,00 | 215,10k | Automatic Disposition | 501,40 | 1,38k | -23,68% |
| 2026-01-20 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -2,24k | 1,10M | Verkauf | 490,77 | 439,63k | -0,51% |
| 2026-01-09 | Dr. Paul A. FriedmanDirector | -24,80k | 12,57M | Derivative Exercise and Sale | 15,80 - 551,24 | 954,00k | - |
| 2026-01-09 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -18,65k | 9,45M | Derivative Exercise and Sale | 15,80 - 551,24 | 436,87k | - |
| 2025-12-10 | Dr. Paul A. FriedmanDirector | -24,80k | 13,30M | Derivative Exercise and Sale | 15,80 - 555,39 | 954,00k | - |
| 2025-12-10 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -18,65k | 10,00M | Derivative Exercise and Sale | 15,80 - 555,39 | 1,11M | - |
| 2025-12-10 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -5,46k | 0,00 | Other Disposition | - | 1,11M | -0,49% |
| 2025-12-03 | Mr. William J. SiboldCEO, President & Director | 47,60k | 0,00 | Derivative Exercise and Retained Stock | - | 102,82k | 86,20% |
| 2025-12-03 | Mr. William J. SiboldCEO, President & Director | -2,40k | 1,38M | Derivative Exercise and Sale | 575,34 | 102,82k | - |
| 2025-12-02 | Ms. Mardi C. DierExec. VP & CFO | -4,17k | 1,36M | Derivative Exercise and Sale | 251,63 - 596,19 | 0,00 | - |
| 2025-11-21 | Ms. Carole HuntsmanExec. VP & Chief Commercial Officer | -1,96k | 1,08M | Verkauf | 547,27 - 564,57 | 0,00 | -100,00% |
| 2025-11-13 | Dr. Richard S. LevyIndependent Director | -8,50k | 4,31M | Derivative Exercise and Sale | 7,36 - 530,21 | 20,48k | - |
| 2025-11-05 | Mr. Kenneth M. BateInsider | -16,58k | 4,63M | Derivative Exercise and Sale | 9,45 - 490,98 | 1,91k | - |
| 2025-09-09 | Mr. William J. SiboldCEO, President & Director | -7,28k | 3,24M | Verkauf | 445,63 | 55,22k | -11,65% |
| 2025-08-21 | Mr. William J. SiboldCEO, President & Director | -7,62k | 3,05M | Automatic Disposition | 400,03 - 401,00 | 50,00k | -13,22% |
| 2025-08-18 | Baker Bros. Advisors LPUnternehmen | 151,71k | 56,70M | Kauf | 353,88 - 392,24 | 1,94M | 8,46% |
| 2025-08-18 | 667, L.P.Unternehmen | 13,98k | 5,22M | Kauf | 353,88 - 392,24 | 198,99k | 7,55% |
| 2025-08-18 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -458,00 | 164,27k | Verkauf | 358,66 | 0,00 | -100,00% |
| 2025-08-18 | Ms. Shannon KelleyExec. VP, Chief Legal Officer & Corporate Secretary | -846,00 | 315,36k | Automatic Disposition | 369,64 - 376,62 | 0,00 | -100,00% |
| 2025-08-15 | Mr. Kenneth M. BateInsider | -10,00k | 3,49M | Derivative Exercise and Sale | 16,46 - 368,56 | 1,91k | - |
| 2025-08-11 | Dr. Paul A. FriedmanDirector | -175,98k | 62,79M | Derivative Exercise and Sale | 9,45 - 374,38 | 954,00k | - |
| 2025-08-11 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -46,46k | 16,07M | Derivative Exercise and Sale | 9,45 - 359,71 | 1,12M | - |
| 2025-07-18 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -1.000,00 | 340,56k | Derivative Exercise and Sale | 9,45 - 350,01 | 1,12M | - |
| 2025-07-18 | Dr. Paul A. FriedmanDirector | -1,40k | 476,81k | Derivative Exercise and Sale | 9,45 - 350,03 | 954,00k | - |
| 2025-07-16 | Dr. Paul A. FriedmanDirector | -28,88k | 9,93M | Derivative Exercise and Sale | 9,45 - 356,62 | 954,00k | - |
| 2025-07-16 | Dr. Rebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director | -29,10k | 10,00M | Derivative Exercise and Sale | 9,45 - 356,52 | 1,12M | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
